De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Syngene International Beheer

Beheer criteriumcontroles 2/4

De CEO Syngene International's is Jonathan Hunt, benoemd in Jan2016, heeft een ambtstermijn van 8.75 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 285.33M, bestaande uit 50% salaris en 50% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.062% van de aandelen van het bedrijf, ter waarde ₹ 225.30M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.7 jaar en 6.2 jaar.

Belangrijke informatie

Jonathan Hunt

Algemeen directeur

₹285.3m

Totale compensatie

Percentage CEO-salaris	50.0%
Dienstverband CEO	8.8yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	7.7yrs
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jonathan Hunt's beloning veranderd ten opzichte van Syngene International's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	₹5b
Mar 31 2024	₹285m	₹143m	₹5b
Dec 31 2023	n/a	n/a	₹5b
Sep 30 2023	n/a	n/a	₹5b
Jun 30 2023	n/a	n/a	₹5b
Mar 31 2023	₹85m	₹85m	₹5b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹4b
Jun 30 2022	n/a	n/a	₹4b
Mar 31 2022	₹76m	₹76m	₹4b
Dec 31 2021	n/a	n/a	₹4b
Sep 30 2021	n/a	n/a	₹4b
Jun 30 2021	n/a	n/a	₹4b
Mar 31 2021	₹65m	₹65m	₹4b
Dec 31 2020	n/a	n/a	₹4b
Sep 30 2020	n/a	n/a	₹4b
Jun 30 2020	n/a	n/a	₹4b
Mar 31 2020	₹66m	₹66m	₹4b
Dec 31 2019	n/a	n/a	₹4b
Sep 30 2019	n/a	n/a	₹4b
Jun 30 2019	n/a	n/a	₹3b
Mar 31 2019	₹90m	₹47m	₹3b
Dec 31 2018	n/a	n/a	₹3b
Sep 30 2018	n/a	n/a	₹3b
Jun 30 2018	n/a	n/a	₹3b
Mar 31 2018	₹94m	₹47m	₹3b

Compensatie versus markt: De totale vergoeding ($USD 3.40M ) Jonathan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 591.73K ).

Compensatie versus inkomsten: De vergoeding van Jonathan is het afgelopen jaar met meer dan 20% gestegen.

CEO

Jonathan Hunt (55 yo)

8.8yrs

Tenure

₹285,330,000

Compensatie

Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Hunt	MD, CEO & Executive Director	8.8yrs	₹285.33m	0.062% ₹ 217.4m
Sibaji Biswas	CFO & Executive Director	4.8yrs	₹34.14m	0.017% ₹ 59.7m
Krishnan G	Head of Investor Relations	no data	geen gegevens	0.0016% ₹ 5.5m
Priyadarshini Mahapatra	Head of Legal	5.3yrs	₹4.72m	0.0024% ₹ 8.4m
Sandeep Nair	Head of Corporate Communications	no data	geen gegevens	geen gegevens
Andrew Webster	Chief Human Resources Officer	1.8yrs	geen gegevens	geen gegevens
Dhananjay Patankar	Head of Pharmaceutical & Biopharmaceutical Development	no data	₹10.80m	geen gegevens
Purushottam Singnurkar	Head of Formulations Development	no data	₹5.50m	0.025% ₹ 87.7m
Ajit Manocha	Head of IT	8.7yrs	geen gegevens	0.00038% ₹ 1.3m
Jayashree Aiyar	Head of Discovery Biology	8.8yrs	geen gegevens	0% ₹ 0
Chetan Tamhankar	Head of Clinical Development & Stability Studies	8.8yrs	geen gegevens	0.0060% ₹ 21.1m
Rajendra Patil	Head of EHSS	6.8yrs	geen gegevens	0.0093% ₹ 32.9m

7.7yrs

Gemiddelde duur

Ervaren management: Het managementteam van 539268 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Hunt	MD, CEO & Executive Director	7.4yrs	₹285.33m	0.062% ₹ 217.4m
Sibaji Biswas	CFO & Executive Director	less than a year	₹34.14m	0.017% ₹ 59.7m
Catherine Rosenberg	Non-Executive Director	24.2yrs	₹8.28m	0.0022% ₹ 7.7m
Kiran Mazumdar-Shaw	Non-Executive Chairperson	no data	₹9.43m	0.0055% ₹ 19.3m
Vinita Bali	Lead Independent Director	7.3yrs	₹8.62m	geen gegevens
Vijay Kuchroo	Independent Director	7.6yrs	₹7.46m	0.012% ₹ 43.9m
Nilanjan Roy	Additional Independent Director	less than a year	geen gegevens	geen gegevens
Kush Parmar	Independent Non Executive Director	3.3yrs	₹6.47m	geen gegevens
Paul Blackburn	Non-Executive Independent Director	10.2yrs	₹9.12m	0.012% ₹ 43.9m
Manja Boerman	Independent Director	less than a year	geen gegevens	geen gegevens
Sharmila Karve	Additional Independent Director	5.2yrs	₹8.46m	geen gegevens

6.2yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 539268 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).

Syngene International Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insider recently sold ₹6.0m worth of stock

MD, CEO & Executive Director recently sold ₹115m worth of stock

Head of Formulations Development recently sold ₹9.6m worth of stock

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹4.9m worth of stock

Syngene International Limited, Annual General Meeting, Jul 24, 2024

Recent updates

Syngene International Limited to Report Q2, 2025 Results on Oct 23, 2024

Insider recently sold ₹6.0m worth of stock

MD, CEO & Executive Director recently sold ₹115m worth of stock

Head of Formulations Development recently sold ₹9.6m worth of stock

Syngene International Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited Approves for the Financial Year Ended March 31, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Proposes Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited to Report Q1, 2025 Results on Jul 24, 2024

New minor risk - Insider selling

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹4.9m worth of stock

Dividend of ₹1.25 announced

Syngene International Limited, Annual General Meeting, Jul 24, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Recommends Final Dividend for the Financial Year 2024

Syngene International Limited to Report Q4, 2024 Results on Apr 24, 2024

Head of IT recently sold ₹1.5m worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024

Insider recently sold ₹9.9m worth of stock

Syngene International Limited to Report Q3, 2024 Results on Jan 25, 2024

Head of Investor Relations recently sold ₹1.7m worth of stock

Head of Investor Relations recently sold ₹1.8m worth of stock

Insider recently sold ₹7.1m worth of stock

Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024

Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director

Second quarter 2024 earnings released: EPS: ₹2.90 (vs ₹2.55 in 2Q 2023)

Syngene International Limited Announces Retirement of Joydeep Kant as Sr. Vice President - Development Services, Effective October 31, 2023

Syngene International Limited to Report Q2, 2024 Results on Oct 17, 2023

Chief Financial Officer recently sold ₹57m worth of stock

Insider recently sold ₹2.4m worth of stock

Price target increased by 8.9% to ₹808

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of ₹1.25 per share at 0.1% yield

Insider recently sold ₹2.3m worth of stock

MD, CEO & Executive Director recently sold ₹166m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹2.1m worth of stock

Insider recently sold ₹4.6m worth of stock

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.9m worth of stock

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Third quarter 2023 earnings released: EPS: ₹2.74 (vs ₹2.57 in 3Q 2022)

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.4m worth of stock

Insider recently sold ₹1.0m worth of stock

Insider recently sold ₹7.8m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹4.3m worth of stock

Syngene International Limited Provides Earnings Guidance for the Year 2022

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹1.1m worth of stock

MD, CEO & Executive Director recently sold ₹20m worth of stock

Chief Human Resources Officer recently sold ₹13m worth of stock

Insider recently sold ₹4.0m worth of stock

Syngene International Limited Approves the Additional Special Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited, Annual General Meeting, Jul 20, 2022

Upcoming dividend of ₹1.00 per share

Syngene International Limited Recommends Special Additional Dividend for the Financial Year Ended March 31, 2022

Insider recently sold ₹1.7m worth of stock

Syngene International Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited to Report Q4, 2022 Results on Apr 27, 2022

Syngene International Limited Appoints Carl Decicco as Additional Director Non-Executive Non-Independent of the Company

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹2.7m worth of stock